These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 28893782

  • 1. Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.
    Yadav R, Bulitta JB, Schneider EK, Shin BS, Velkov T, Nation RL, Landersdorfer CB.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893782
    [Abstract] [Full Text] [Related]

  • 2. Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling.
    Yadav R, Bulitta JB, Nation RL, Landersdorfer CB.
    Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821448
    [Abstract] [Full Text] [Related]

  • 3. Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii.
    Yadav R, Landersdorfer CB, Nation RL, Boyce JD, Bulitta JB.
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2286-98. PubMed ID: 25645842
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of Pharmacokinetic/Pharmacodynamic Model-Based Optimized Combination Regimens against Multidrug-Resistant Pseudomonas aeruginosa in a Murine Thigh Infection Model by Using Humanized Dosing Schemes.
    Yadav R, Bulitta JB, Wang J, Nation RL, Landersdorfer CB.
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993331
    [Abstract] [Full Text] [Related]

  • 5. Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.
    Yadav R, Bergen PJ, Rogers KE, Kirkpatrick CMJ, Wallis SC, Huang Y, Bulitta JB, Paterson DL, Lipman J, Nation RL, Roberts JA, Landersdorfer CB.
    Antimicrob Agents Chemother; 2019 Dec 20; 64(1):. PubMed ID: 31636062
    [Abstract] [Full Text] [Related]

  • 6. Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model.
    Landersdorfer CB, Rees VE, Yadav R, Rogers KE, Kim TH, Bergen PJ, Cheah SE, Boyce JD, Peleg AY, Oliver A, Shin BS, Nation RL, Bulitta JB.
    Antimicrob Agents Chemother; 2018 Apr 20; 62(4):. PubMed ID: 29437610
    [Abstract] [Full Text] [Related]

  • 7. Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling.
    Bulitta JB, Ly NS, Landersdorfer CB, Wanigaratne NA, Velkov T, Yadav R, Oliver A, Martin L, Shin BS, Forrest A, Tsuji BT.
    Antimicrob Agents Chemother; 2015 Apr 20; 59(4):2315-27. PubMed ID: 25645838
    [Abstract] [Full Text] [Related]

  • 8. Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.
    Yadav R, Rogers KE, Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB.
    Antimicrob Agents Chemother; 2018 May 20; 62(5):. PubMed ID: 29463528
    [Abstract] [Full Text] [Related]

  • 9. Combating Carbapenem-Resistant Acinetobacter baumannii by an Optimized Imipenem-plus-Tobramycin Dosage Regimen: Prospective Validation via Hollow-Fiber Infection and Mathematical Modeling.
    Landersdorfer CB, Yadav R, Rogers KE, Kim TH, Shin BS, Boyce JD, Nation RL, Bulitta JB.
    Antimicrob Agents Chemother; 2018 Apr 20; 62(4):. PubMed ID: 29339388
    [Abstract] [Full Text] [Related]

  • 10. [In vitro combination effects of doripenem with aminoglycoside or ciprofloxacin against Pseudomonas aeruginosa].
    Anan N, Toba S, Ito A, Nakamura R, Tsuji M.
    Jpn J Antibiot; 2011 Aug 20; 64(4):203-16. PubMed ID: 22066345
    [Abstract] [Full Text] [Related]

  • 11. Synergistic effects of inhaled aztreonam plus tobramycin on hypermutable cystic fibrosis Pseudomonas aeruginosa isolates in a dynamic biofilm model evaluated by mechanism-based modelling and whole genome sequencing.
    Breen SKJ, Harper M, López-Causapé C, Rogers KE, Tait JR, Smallman TR, Lang Y, Lee WL, Zhou J, Zhang Y, Bulitta JB, Nation RL, Oliver A, Boyce JD, Landersdorfer CB.
    Int J Antimicrob Agents; 2024 Jun 20; 63(6):107161. PubMed ID: 38561094
    [Abstract] [Full Text] [Related]

  • 12. Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
    Bilal H, Tait JR, Lang Y, Zhou J, Bergen PJ, Peleg AY, Bulitta JB, Oliver A, Nation RL, Landersdorfer CB.
    Antimicrob Agents Chemother; 2022 Mar 15; 66(3):e0220321. PubMed ID: 35041509
    [Abstract] [Full Text] [Related]

  • 13. The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential.
    Maiden MM, Zachos MP, Waters CM.
    J Antimicrob Chemother; 2019 Apr 01; 74(4):894-906. PubMed ID: 30624737
    [Abstract] [Full Text] [Related]

  • 14. Beta-lactamase induction and aminoglycoside susceptibility in Pseudomonas aeruginosa.
    Stratton CW, Weeks LS, Tausk F.
    J Antimicrob Chemother; 1987 Jan 01; 19(1):21-5. PubMed ID: 3104276
    [Abstract] [Full Text] [Related]

  • 15. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.
    Ly NS, Bulitta JB, Rao GG, Landersdorfer CB, Holden PN, Forrest A, Bergen PJ, Nation RL, Li J, Tsuji BT.
    J Antimicrob Chemother; 2015 May 01; 70(5):1434-42. PubMed ID: 25712313
    [Abstract] [Full Text] [Related]

  • 16. [Antimicrobial activity of carbapenems and the combined effect with aminoglycoside against recent clinical isolates of Pseudomonas aeruginosa].
    Tasaka K, Ishida A, Chinzei T.
    Jpn J Antibiot; 2002 Apr 01; 55(2):181-6. PubMed ID: 12071095
    [Abstract] [Full Text] [Related]

  • 17. [In vitro interaction of piperacillin and imipenem/cilastatin combined with aminoglycosides against Pseudomonas aeruginosa].
    Yamashiro Y, Ogake N, Takahata M, Minami S.
    Jpn J Antibiot; 2000 Apr 01; 53(4):194-200. PubMed ID: 10868299
    [Abstract] [Full Text] [Related]

  • 18. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model.
    Bilal H, Bergen PJ, Kim TH, Chung SE, Peleg AY, Oliver A, Nation RL, Landersdorfer CB.
    Antimicrob Agents Chemother; 2019 Nov 01; 63(11):. PubMed ID: 31427301
    [Abstract] [Full Text] [Related]

  • 19. Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa.
    Gelfand MS, Cleveland KO, Mazumder SA.
    J Antimicrob Chemother; 2009 Jun 01; 63(6):1297-9. PubMed ID: 19369268
    [No Abstract] [Full Text] [Related]

  • 20. Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.
    Weiss K, Lapointe JR.
    Antimicrob Agents Chemother; 1995 Nov 01; 39(11):2411-4. PubMed ID: 8585718
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.